Literature DB >> 33692390

Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities.

Maria G Noval1, Maria E Kaczmarek1, Akiko Koide2,3, Bruno A Rodriguez-Rodriguez1, Ping Louie4, Takuya Tada1, Takamitsu Hattori2,5, Tatyana Panchenko2, Larizbeth A Romero5, Kai Wen Teng2, Andrew Bazley5, Maren de Vries1, Marie I Samanovic6, Jeffrey N Weiser1, Ioannis Aifantis2,4, Joan Cangiarella4, Mark J Mulligan6, Ludovic Desvignes3,6,7, Meike Dittmann1, Nathaniel R Landau1, Maria Aguero-Rosenfeld4, Shohei Koide8,9, Kenneth A Stapleford10.   

Abstract

Understanding antibody responses to SARS-CoV-2 is indispensable for the development of containment measures to overcome the current COVID-19 pandemic. Recent studies showed that serum from convalescent patients can display variable neutralization capacities. Still, it remains unclear whether there are specific signatures that can be used to predict neutralization. Here, we performed a detailed analysis of sera from a cohort of 101 recovered healthcare workers and we addressed their SARS-CoV-2 antibody response by ELISA against SARS-CoV-2 Spike receptor binding domain and nucleoprotein. Both ELISA methods detected sustained levels of serum IgG against both antigens. Yet, the majority of individuals from our cohort generated antibodies with low neutralization capacity and only 6% showed high neutralizing titers against both authentic SARS-CoV-2 virus and the Spike pseudotyped virus. Interestingly, higher neutralizing sera correlate with detection of -IgG, IgM and IgA antibodies against both antigens, while individuals with positive IgG alone showed poor neutralization response. These results suggest that having a broader repertoire of antibodies may contribute to more potent SARS-CoV-2 neutralization. Altogether, our work provides a cross sectional snapshot of the SARS-CoV-2 neutralizing antibody response in recovered healthcare workers and provides preliminary evidence that possessing multiple antibody isotypes can play an important role in predicting SARS-CoV-2 neutralization.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33692390      PMCID: PMC7946906          DOI: 10.1038/s41598-021-84913-3

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.996


  35 in total

1.  Kinetics of viral load and antibody response in relation to COVID-19 severity.

Authors:  Yanqun Wang; Lu Zhang; Ling Sang; Feng Ye; Shicong Ruan; Bei Zhong; Tie Song; Abeer N Alshukairi; Rongchang Chen; Zhaoyong Zhang; Mian Gan; Airu Zhu; Yongbo Huang; Ling Luo; Chris Ka Pun Mok; Manal M Al Gethamy; Haitao Tan; Zhengtu Li; Xiaofang Huang; Fang Li; Jing Sun; Yanjun Zhang; Liyan Wen; Yuming Li; Zhao Chen; Zhen Zhuang; Jianfen Zhuo; Chunke Chen; Lijun Kuang; Junxiang Wang; Huibin Lv; Yongliang Jiang; Min Li; Yimin Lin; Ying Deng; Lan Tang; Jieling Liang; Jicheng Huang; Stanley Perlman; Nanshan Zhong; Jingxian Zhao; J S Malik Peiris; Yimin Li; Jincun Zhao
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

2.  Antibody responses to SARS-CoV-2 short-lived.

Authors:  Nicolas Vabret
Journal:  Nat Rev Immunol       Date:  2020-09       Impact factor: 53.106

3.  Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020.

Authors:  Fiona P Havers; Carrie Reed; Travis Lim; Joel M Montgomery; John D Klena; Aron J Hall; Alicia M Fry; Deborah L Cannon; Cheng-Feng Chiang; Aridth Gibbons; Inna Krapiunaya; Maria Morales-Betoulle; Katherine Roguski; Mohammad Ata Ur Rasheed; Brandi Freeman; Sandra Lester; Lisa Mills; Darin S Carroll; S Michele Owen; Jeffrey A Johnson; Vera Semenova; Carina Blackmore; Debra Blog; Shua J Chai; Angela Dunn; Julie Hand; Seema Jain; Scott Lindquist; Ruth Lynfield; Scott Pritchard; Theresa Sokol; Lynn Sosa; George Turabelidze; Sharon M Watkins; John Wiesman; Randall W Williams; Stephanie Yendell; Jarad Schiffer; Natalie J Thornburg
Journal:  JAMA Intern Med       Date:  2020-07-21       Impact factor: 21.873

4.  Commercial Serology Assays Predict Neutralization Activity against SARS-CoV-2.

Authors:  Raymond T Suhandynata; Melissa A Hoffman; Deli Huang; Jenny T Tran; Michael J Kelner; Sharon L Reed; Ronald W McLawhon; James E Voss; David Nemazee; Robert L Fitzgerald
Journal:  Clin Chem       Date:  2021-01-30       Impact factor: 8.327

Review 5.  Immunology of COVID-19: Current State of the Science.

Authors:  Nicolas Vabret; Graham J Britton; Conor Gruber; Samarth Hegde; Joel Kim; Maria Kuksin; Rachel Levantovsky; Louise Malle; Alvaro Moreira; Matthew D Park; Luisanna Pia; Emma Risson; Miriam Saffern; Bérengère Salomé; Myvizhi Esai Selvan; Matthew P Spindler; Jessica Tan; Verena van der Heide; Jill K Gregory; Konstantina Alexandropoulos; Nina Bhardwaj; Brian D Brown; Benjamin Greenbaum; Zeynep H Gümüş; Dirk Homann; Amir Horowitz; Alice O Kamphorst; Maria A Curotto de Lafaille; Saurabh Mehandru; Miriam Merad; Robert M Samstein
Journal:  Immunity       Date:  2020-05-06       Impact factor: 31.745

Review 6.  Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19.

Authors:  Gregory D Sempowski; Kevin O Saunders; Priyamvada Acharya; Kevin J Wiehe; Barton F Haynes
Journal:  Cell       Date:  2020-05-27       Impact factor: 41.582

7.  Estimated Community Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April 28-May 3, 2020.

Authors:  Holly M Biggs; Jennifer B Harris; Lucy Breakwell; F Scott Dahlgren; Glen R Abedi; Christine M Szablewski; Jan Drobeniuc; Nirma D Bustamante; Olivia Almendares; Amy H Schnall; Zunera Gilani; Tiffany Smith; Laura Gieraltowski; Jeffrey A Johnson; Kristina L Bajema; Kelsey McDavid; Ilana J Schafer; Vickie Sullivan; Lili Punkova; Alexandra Tejada-Strop; Raiza Amiling; Claire P Mattison; Margaret M Cortese; S Elizabeth Ford; Lynn A Paxton; Cherie Drenzek; Jacqueline E Tate
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-07-24       Impact factor: 17.586

8.  Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients.

Authors:  Baweleta Isho; Kento T Abe; Michelle Zuo; Alainna J Jamal; Bhavisha Rathod; Jenny H Wang; Zhijie Li; Gary Chao; Olga L Rojas; Yeo Myong Bang; Annie Pu; Natasha Christie-Holmes; Christian Gervais; Derek Ceccarelli; Payman Samavarchi-Tehrani; Furkan Guvenc; Patrick Budylowski; Angel Li; Aimee Paterson; Feng Yun Yue; Lina M Marin; Lauren Caldwell; Jeffrey L Wrana; Karen Colwill; Frank Sicheri; Samira Mubareka; Scott D Gray-Owen; Steven J Drews; Walter L Siqueira; Miriam Barrios-Rodiles; Mario Ostrowski; James M Rini; Yves Durocher; Allison J McGeer; Jennifer L Gommerman; Anne-Claude Gingras
Journal:  Sci Immunol       Date:  2020-10-08

9.  Duration of antibody responses after severe acute respiratory syndrome.

Authors:  Li-Ping Wu; Nai-Chang Wang; Yi-Hua Chang; Xiang-Yi Tian; Dan-Yu Na; Li-Yuan Zhang; Lei Zheng; Tao Lan; Lin-Fa Wang; Guo-Dong Liang
Journal:  Emerg Infect Dis       Date:  2007-10       Impact factor: 6.883

10.  Potently neutralizing and protective human antibodies against SARS-CoV-2.

Authors:  Seth J Zost; Pavlo Gilchuk; James Brett Case; Elad Binshtein; Rita E Chen; Joseph P Nkolola; Alexandra Schäfer; Joseph X Reidy; Andrew Trivette; Rachel S Nargi; Rachel E Sutton; Naveenchandra Suryadevara; David R Martinez; Lauren E Williamson; Elaine C Chen; Taylor Jones; Samuel Day; Luke Myers; Ahmed O Hassan; Natasha M Kafai; Emma S Winkler; Julie M Fox; Swathi Shrihari; Benjamin K Mueller; Jens Meiler; Abishek Chandrashekar; Noe B Mercado; James J Steinhardt; Kuishu Ren; Yueh-Ming Loo; Nicole L Kallewaard; Broc T McCune; Shamus P Keeler; Michael J Holtzman; Dan H Barouch; Lisa E Gralinski; Ralph S Baric; Larissa B Thackray; Michael S Diamond; Robert H Carnahan; James E Crowe
Journal:  Nature       Date:  2020-07-15       Impact factor: 69.504

View more
  13 in total

1.  Isotyping and quantitation of the humoral immune response to SARS-CoV-2.

Authors:  Krystal A Goyins; Jieh-Juen Yu; Sara B Papp; Rachel Beddard; Ashlesh K Murthy; James P Chambers; Bernard P Arulanandam
Journal:  Exp Biol Med (Maywood)       Date:  2022-04-02

2.  Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies.

Authors:  Takuya Tada; Hao Zhou; Marie I Samanovic; Belinda M Dcosta; Amber Cornelius; Ramin S Herati; Mark J Mulligan; Nathaniel R Landau
Journal:  Front Immunol       Date:  2022-03-08       Impact factor: 8.786

3.  Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies.

Authors:  Takuya Tada; Hao Zhou; Belinda M Dcosta; Marie I Samanovic; Vidya Chivukula; Ramin S Herati; Stevan R Hubbard; Mark J Mulligan; Nathaniel R Landau
Journal:  EBioMedicine       Date:  2022-04       Impact factor: 11.205

4.  Host Predictors of Broadly Cross-Reactive Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern Differ Between Infection and Vaccination.

Authors:  Li Tang; Sean Cherry; Elaine I Tuomanen; Ericka Kirkpatrick Roubidoux; Chun Yang Lin; Kim J Allison; Ashleigh Gowen; Pamela Freiden; E Kaitlynn Allen; Yin Su; Aditya H Gaur; Jeremie H Estepp; Maureen A McGargill; Florian Krammer; Paul G Thomas; Stacey Schultz-Cherry; Joshua Wolf
Journal:  Clin Infect Dis       Date:  2022-08-24       Impact factor: 20.999

5.  Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer.

Authors:  Vivek Naranbhai; Kerri J St Denis; Evan C Lam; Onosereme Ofoman; Wilfredo F Garcia-Beltran; Cristhian B Mairena; Atul K Bhan; Justin F Gainor; Alejandro B Balazs; A John Iafrate
Journal:  Cancer Cell       Date:  2022-01-05       Impact factor: 31.743

6.  Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays.

Authors:  Sabine Chapuy-Regaud; Marcel Miédougé; Florence Abravanel; Isabelle Da Silva; Marion Porcheron; Judith Fillaux; Chloé Diméglio; Jacques Izopet
Journal:  Microbiol Spectr       Date:  2021-12-22

7.  Persistence of SARS-CoV-2 total immunoglobulins in a series of convalescent plasma and blood donors.

Authors:  M Carmen Martin; Ana Jimenez; Nuria Ortega; Alba Parrado; Isabel Page; M Isabel Gonzalez; Lydia Blanco-Peris
Journal:  PLoS One       Date:  2022-02-24       Impact factor: 3.240

8.  Kinetics and persistence of anti-SARS-CoV-2 neutralisation and antibodies after BNT162b2 vaccination in a Swiss cohort.

Authors:  Lara Šošić; Marta Paolucci; Agathe Duda; Fabio Hasler; Senta M Walton; Thomas M Kündig; Pål Johansen
Journal:  Immun Inflamm Dis       Date:  2021-12-29

Review 9.  Actions and attitudes on the immunized patients against SARS-CoV-2.

Authors:  P De Lucas Ramos; A García-Botella; A García-Lledó; J Gómez-Pavón; J González Del Castillo; T Hernández-Sampelayo; M C Martín-Delgado; F J Martín Sánchez; M Martínez-Sellés; J M Molero García; S Moreno Guillén; F J Rodríguez-Artalejo; J Ruiz-Galiana; R Cantón; E Bouza
Journal:  Rev Esp Quimioter       Date:  2021-10-21       Impact factor: 1.553

10.  B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies.

Authors:  Hao Zhou; Belinda M Dcosta; Marie I Samanovic; Mark J Mulligan; Nathaniel R Landau; Takuya Tada
Journal:  mBio       Date:  2021-07-27       Impact factor: 7.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.